CN1960734A - 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 - Google Patents

使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 Download PDF

Info

Publication number
CN1960734A
CN1960734A CNA2005800173160A CN200580017316A CN1960734A CN 1960734 A CN1960734 A CN 1960734A CN A2005800173160 A CNA2005800173160 A CN A2005800173160A CN 200580017316 A CN200580017316 A CN 200580017316A CN 1960734 A CN1960734 A CN 1960734A
Authority
CN
China
Prior art keywords
treatment
propargyl
pdx
cell lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800173160A
Other languages
English (en)
Chinese (zh)
Inventor
O·A·澳康诺尔
F·西罗特纳克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1960734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN1960734A publication Critical patent/CN1960734A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2005800173160A 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 Pending CN1960734A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
US60/521,593 2004-05-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210342831.8A Division CN102824346B (zh) 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤

Publications (1)

Publication Number Publication Date
CN1960734A true CN1960734A (zh) 2007-05-09

Family

ID=34971703

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800173160A Pending CN1960734A (zh) 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤
CN201210342831.8A Expired - Lifetime CN102824346B (zh) 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210342831.8A Expired - Lifetime CN102824346B (zh) 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤

Country Status (23)

Country Link
US (4) US7622470B2 (cg-RX-API-DMAC7.html)
EP (1) EP1750716B1 (cg-RX-API-DMAC7.html)
JP (1) JP5005532B2 (cg-RX-API-DMAC7.html)
KR (1) KR101189693B1 (cg-RX-API-DMAC7.html)
CN (2) CN1960734A (cg-RX-API-DMAC7.html)
AT (1) ATE405272T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005249516B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510895A (cg-RX-API-DMAC7.html)
CA (1) CA2565968C (cg-RX-API-DMAC7.html)
DE (1) DE602005009176D1 (cg-RX-API-DMAC7.html)
DK (1) DK1750716T3 (cg-RX-API-DMAC7.html)
ES (1) ES2313365T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080569T3 (cg-RX-API-DMAC7.html)
ME (1) ME01087B (cg-RX-API-DMAC7.html)
MX (1) MXPA06013559A (cg-RX-API-DMAC7.html)
NO (1) NO337276B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ551082A (cg-RX-API-DMAC7.html)
PL (1) PL1750716T3 (cg-RX-API-DMAC7.html)
PT (1) PT1750716E (cg-RX-API-DMAC7.html)
RS (1) RS50622B (cg-RX-API-DMAC7.html)
SI (1) SI1750716T1 (cg-RX-API-DMAC7.html)
WO (2) WO2005117892A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609266B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984940A (zh) * 2010-06-02 2013-03-20 阿罗斯治疗公司 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法
CN103068237A (zh) * 2010-08-10 2013-04-24 阿罗斯治疗公司 使用10-炔丙基-10-去氮杂氨基蝶呤延长无进展存活期的方法
CN103274943A (zh) * 2013-05-24 2013-09-04 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
BRPI0510895A (pt) 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
EP2179284B1 (en) 2007-07-31 2016-09-28 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
WO2011096947A1 (en) * 2010-02-02 2011-08-11 Allos Therapeutics, Inc. Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
US11439643B2 (en) 2015-06-16 2022-09-13 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
CA2055813A1 (en) * 1990-11-20 1992-05-21 Dariush Davalian Cyclosporin immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6028071A (en) * 1996-07-17 2000-02-22 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
BRPI0510895A (pt) * 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984940A (zh) * 2010-06-02 2013-03-20 阿罗斯治疗公司 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法
CN102984940B (zh) * 2010-06-02 2016-01-13 阿罗斯治疗公司 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法
CN103068237A (zh) * 2010-08-10 2013-04-24 阿罗斯治疗公司 使用10-炔丙基-10-去氮杂氨基蝶呤延长无进展存活期的方法
CN103274943A (zh) * 2013-05-24 2013-09-04 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法

Also Published As

Publication number Publication date
DE602005009176D1 (de) 2008-10-02
MXPA06013559A (es) 2007-04-24
SI1750716T1 (sl) 2009-06-30
ME01087B (me) 2012-12-20
WO2005117892A1 (en) 2005-12-15
NZ576849A (en) 2011-03-31
ES2313365T3 (es) 2009-03-01
US20050267117A1 (en) 2005-12-01
US7939530B2 (en) 2011-05-10
HRP20080569T3 (en) 2008-12-31
US20100120777A1 (en) 2010-05-13
ZA200609266B (en) 2008-12-31
RS50622B (sr) 2010-06-30
EP1750716A1 (en) 2007-02-14
PT1750716E (pt) 2008-11-04
US20080058280A1 (en) 2008-03-06
AU2005249516B2 (en) 2010-11-18
NO337276B1 (no) 2016-02-29
ATE405272T1 (de) 2008-09-15
PL1750716T3 (pl) 2009-01-30
DK1750716T3 (da) 2008-12-08
US8299078B2 (en) 2012-10-30
KR20110081327A (ko) 2011-07-13
US20130053391A1 (en) 2013-02-28
CN102824346A (zh) 2012-12-19
JP2008501038A (ja) 2008-01-17
HK1177901A1 (en) 2013-08-30
BRPI0510895A (pt) 2007-11-27
NZ551082A (en) 2009-06-26
WO2005117891A1 (en) 2005-12-15
JP5005532B2 (ja) 2012-08-22
KR101189693B1 (ko) 2012-10-10
EP1750716B1 (en) 2008-08-20
CA2565968C (en) 2013-01-08
US7622470B2 (en) 2009-11-24
AU2005249516A1 (en) 2005-12-15
CA2565968A1 (en) 2005-12-15
NO20065971L (no) 2006-12-22
CN102824346B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
EP3802534B1 (en) Tricyclic heterocyclic compounds as sting activators
TWI268923B (en) N6 heterocyclic 8-modified adenosine derivatives
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
JP2021038241A (ja) N−(3,5−ジメトキシフェニル)−n’−(1−メチルエチル)−n−[3−(1−メチル−1h−ピラゾール−4−イル)キノキサリン−6−イル]エタン−1,2−ジアミンを含んでなる医薬組成物
US20130053391A1 (en) Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
CN104066723B (zh) 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用
EA027990B1 (ru) Замещенные (2r,3r,5r)-3-гидрокси(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
US20110104186A1 (en) Small molecule immunopotentiators and assays for their detection
CN113717245A (zh) 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用
Weis et al. L-ribofuranosyl nucleosides
CN101454309B (zh) 焦谷氨酸衍生物的合成和用途
CN114539278A (zh) IL-15抑制剂Neoprzewaquinone A,及其筛选方法和应用
EP3740287B1 (en) Treatments for cachexia
CN115038701A (zh) Jak抑制剂的晶型及其应用
CN1188413C (zh) 治疗疼痛的化合物
CN113662945B (zh) 用于治疗乙型肝炎的组合
CN120737091B (zh) 一种以7-脱氮鸟嘌呤为骨架的化合物、药物组合物及用途
CN106146408B (zh) 2,5,6位取代嘧啶酮衍生物的制备方法及其作为抗乙肝病毒药物的应用
JP2002536448A (ja) 治療用ヌクレオシド化合物
CN121041265A (zh) 化合物在制备抗结直肠癌腹膜转移药物中的应用
JPH0395166A (ja) イソキサゾロン誘導体含有脳機能改善剤
HK1177901B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2021102343A1 (en) Solid dose pharmaceutical composition
CN114560904A (zh) IL-15抑制剂Diosgenin,及其筛选方法和应用
HK40050938A (en) Tricyclic heterocyclic compounds as sting activators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070509